Lenacapavir

Major

Lenacapavir Fexofenadine Allegra Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Finerenone Kerendia Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Futibatinib Lytgobi Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Gilteritinib Xospata Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Hydrocortisone Ala-Cort Increased CYP3A substrate/systemic corticosteroid exposure and an increased risk of Cushing's syndrome and adrenal suppression Details Lenacapavir Hydrocortisone Injection A-Hydrocort® Increased CYP3A substrate/systemic corticosteroid exposure and an increased risk of Cushing's syndrome and adrenal suppression Details Lenacapavir Ibrexafungerp Brexafemme Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Ibrutinib Imbruvica Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Infigratinib Truseltiq Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Ivabradine Corlanor Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Lenacapavir Letermovir Injection Prevymis Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Linagliptin Tradjenta Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Lenacapavir Lovastatin Altocor® Increased lovastatin exposure Details Lenacapavir Lumateperone Caplyta Increased lumateperone exposure and increased risk of lumateperone-related adverse reactions Details Lenacapavir Lurasidone Latuda Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Lurbinectedin Injection Zepzelca Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Lenacapavir Maraviroc Selzentry Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Lenacapavir Methylergonovine Methergine Increased methylergonovine exposure Details Lenacapavir Midazolam Nasal Spray Nayzilam Increased midazolam exposure Details Lenacapavir Midazolam Injection Nayzilam Increased midazolam exposure Details Lenacapavir Midostaurin Rydapt Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Mitapivat Aqvesme Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir, incr... Details Lenacapavir Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Lenacapavir Nafcillin Injection Unipen® Injection Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Naldemedine Symproic Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Naloxegol Movantik Increased naloxegol exposure Details Lenacapavir Nevirapine Viramune Reduced lenacapavir exposure and reduced efficacy of lenacapavir Details Lenacapavir Nifedipine Adalat® Increased NIFEdipine exposure Details Lenacapavir Nintedanib Ofev Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Nisoldipine Sular Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details